August 2020

Managing narcolepsy via behavioral strategies to improve excessive daytime sleepiness may be challenging but has shown some added efficacy when combined with pharmacological treatment for EDS.

New biomarkers of disease activity may help better vet investigational therapies aimed at slowing the insidious neurodegeneration seen in primary progressive multiple sclerosis.

With a positive track record in ALS, the investigational agent now sets its sights on the Alzheimer disease pipeline.

Could expanding insights into the pathophysiology of autoimmune epilepsy offer seizure-free hope for patients?

Howard Fillit, MD, founding executive director and chief science officer of the Alzheimer's Drug Discovery Foundation and clinical professor of geriatric medicine and palliative care, medicine, and neuroscience at Mount Sinai School of Medicine, detailed the role telemedicine plays in treating Alzheimer disease.

A group of international experts in the treatment of multiple sclerosis offer their varying viewpoints on the history, identification, and management of the disease.

Efforts to cut through regulatory red tape will help ensure earlier access to potentially lifesaving treatments.